MCID: PRK059
MIFTS: 52

Parkinson Disease 8 malady

Categories: Genetic diseases, Neuronal diseases, Mental diseases, Rare diseases, Metabolic diseases

Aliases & Classifications for Parkinson Disease 8

About this section

Aliases & Descriptions for Parkinson Disease 8:

Name: Parkinson Disease 8 51 69 12 67
Autosomal Dominant Parkinson Disease 8 11 26 13
 
Park8 69

Characteristics:

HPO:

63
parkinson disease 8:
Inheritance: autosomal dominant inheritance
Onset and clinical course: slow progression, incomplete penetrance

Classifications:



External Ids:

OMIM51 607060
Disease Ontology11 DOID:0060371
MedGen36 C1846862
MeSH38 D010300

Summaries for Parkinson Disease 8

About this section
UniProtKB/Swiss-Prot:69 Parkinson disease 8: A slowly progressive neurodegenerative disorder characterized by bradykinesia, rigidity, resting tremor, postural instability, neuronal loss in the substantia nigra, and the presence of neurofibrillary MAPT (tau)-positive and Lewy bodies in some patients.

MalaCards based summary: Parkinson Disease 8, also known as autosomal dominant parkinson disease 8, is related to parkinson disease, late-onset and lrrk2-related parkinson disease, and has symptoms including dementia, rigidity and bradykinesia. An important gene associated with Parkinson Disease 8 is LRRK2 (Leucine Rich Repeat Kinase 2), and among its related pathways are Androgen receptor signaling pathway and Alpha-synuclein signaling. Affiliated tissues include brain, eye and testes, and related mouse phenotypes are taste/olfaction and cardiovascular system.

Disease Ontology:11 A Parkinson's disease that has material basis in heterozygous mutation in the dardarin encoding gene (LRRK2) on chromosome 12q12.

Description from OMIM:51 607060

Related Diseases for Parkinson Disease 8

About this section

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 7, Autosomal Recessive Early-Onset Parkinson Disease 6, Early Onset
Parkinson Disease 19, Juvenile-Onset Parkinson Disease 10
Parkinson Disease 16 Parkinson Disease 13
Parkinson Disease 11 Parkinson Disease 21
Parkinson Disease 18 Parkinson Disease 5
Parkinson Disease 4 Parkinson Disease 1
Parkinson Disease, Juvenile, Type 2 parkinson disease 8
Parkinson Disease 17 Parkinson Disease 20, Early-Onset
Parkinson Disease 15, Autosomal Recessive Parkinson Disease 14, Autosomal Recessive
Parkinson Disease 12 Lrrk2-Related Parkinson Disease
Parkinson Disease Type 3 Parkinson Disease Type 9
Dnajc6-Related Parkinson Disease Eif4g1-Related Parkinson Disease
Gigyf2-Related Parkinson Disease Pla2g6-Related Parkinson Disease
Synj1-Related Parkinson Disease Fbxo7-Related Parkinson Disease
Htra2-Related Parkinson Disease Park7-Related Parkinson Disease
Snca-Related Parkinson Disease Vps35-Related Parkinson Disease
Hereditary Late-Onset Parkinson Disease Parkinson Disease 22
Parkinson Disease 23, Autosomal Recessive, Early Onset

Diseases related to Parkinson Disease 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 28)
idRelated DiseaseScoreTop Affiliating Genes
1parkinson disease, late-onset29.2LRRK2, PARK2, PARK7, PINK1, SNCA
2lrrk2-related parkinson disease11.1
3angelman syndrome due to imprinting defect in 15q11-q1310.1LRRK2, SNCA
4erythematosquamous dermatosis10.0LRRK2, SNCA
5anti-p200 pemphigoid10.0LRRK2, SNCA
6epileptic hemiplegia9.9PARK2, SNCA
7aspartylglucosaminuria9.9LRRK2, PARK2
8ovarian cancer, somatic9.8CTNNB1, PARK2
9whiplash9.7LRRK2, PARK2, SNCA
10parkinson disease 19.7LRRK2, PARK2, SNCA
11vaginal tubular adenoma9.7CTNNB1, LRRK2, SNCA
12essential tremor9.7LRRK2, PARK2, SNCA
13polycystic kidney disease 29.7LRRK2, PARK2, SNCA
14pick disease9.6LRRK2, PARK2, SNCA
15hypotrichosis 79.5PARK2, SNCA
16kufor-rakeb syndrome9.5PARK7, PINK1
17klippel-feil syndrome 4, autosomal recessive, with myopathy and facial dysmorphism9.4PARK2, PARK7, SNCA
18phka2-related phosphorylase kinase deficiency9.0LRRK2, PARK2, PARK7, SNCA
19meier-gorlin syndrome 59.0LRRK2, PARK2, PARK7, SNCA
20parkinson disease 6, early onset9.0LRRK2, PARK2, PARK7, PINK1
21coenzyme q10 deficiency, primary, 18.8PARK2, PARK7, PINK1, SNCA
22parkinson disease 108.5LRRK2, PARK2, PARK7, PINK1, SNCA
23celiac disease 128.5LRRK2, PARK2, PARK7, PINK1, SNCA
24mast syndrome8.5LRRK2, PARK2, PARK7, PINK1, SNCA
25adrenal gland pheochromocytoma8.5LRRK2, PARK2, PARK7, PINK1, SNCA
26angiomyolipoma8.5LRRK2, PARK2, PARK7, PINK1, SNCA
27chronic intestinal vascular insufficiency8.5LRRK2, PARK2, PARK7, PINK1, SNCA
28epilepsy, progressive myoclonic 1b8.1CTNNB1, LRRK2, PARK2, PARK7, PINK1, SNCA

Graphical network of the top 20 diseases related to Parkinson Disease 8:



Diseases related to parkinson disease 8

Symptoms for Parkinson Disease 8

About this section

Symptoms by clinical synopsis from OMIM:

607060

Clinical features from OMIM:

607060

Human phenotypes related to Parkinson Disease 8:

 63 (show all 8)
id Description HPO Frequency HPO Source Accession
1 dementia63 HP:0000726
2 rigidity63 HP:0002063
3 bradykinesia63 HP:0002067
4 postural instability63 HP:0002172
5 resting tremor63 HP:0002322
6 parkinsonism with favorable response to dopaminergic medication63 HP:0002548
7 hyposmia63 HP:0004409
8 substantia nigra gliosis63 HP:0011960

UMLS symptoms related to Parkinson Disease 8:


muscle rigidity, bradykinesia, sense of smell impaired

Drugs & Therapeutics for Parkinson Disease 8

About this section

Drugs for Parkinson Disease 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 212)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 3, Phase 2, Phase 1375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
RasagilineapprovedPhase 4, Phase 3, Phase 154136236-51-63052776
Synonyms:
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
(1R)-N-Propargylindan-1-amine
(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
(R)-Indan-1-yl-prop-2-ynyl-amine
(R)-N-2-Propynyl-1-indanamine
136236-51-6
1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
AC-723
AC1MHJZT
Azilect
Azilect (TN)
CHEBI:45357
 
CHEMBL887
CID3052776
D08469
DB01367
LS-186771
LS-187776
MolPort-003-850-132
NCGC00168774-01
RAS
Rasagiline (INN)
Rasagiline [INN]
UNII-003N66TS6T
ZINC19875504
rasagiline
3
LevodopaapprovedPhase 4, Phase 3, Phase 2, Phase 138859-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
4
Pramipexoleapproved, investigationalPhase 4, Phase 3139104632-26-059868, 119570
Synonyms:
(-)-Pramipexole
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
104632-26-0
111GE001
2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
2-amino-6-propylaminotetrahydrobenzothiazole
AC1L3P1T
BIDD:GT0250
C10H17N3S
CHEBI:8356
CHEMBL301265
CID119570
CPD000449298
D05575
DivK1c_006916
Furfuryl Acetate
HMS2051A21
HMS2090C15
KBio1_001860
KBio2_002340
KBio2_004908
 
KBio2_007476
KBioSS_002343
LS-40722
MLS000758250
MLS001423952
Mirapex
MolPort-003-849-957
NCGC00167441-01
Pramipexol
Pramipexol [Spanish]
Pramipexole
Pramipexole (USAN/INN)
Pramipexole 2HCl Monohydrate
Pramipexole [USAN:INN]
Pramipexole hydrochloride
Pramipexolum
Pramipexolum [Latin]
SAM001247006
SBB070477
SMR000449298
SND-919
SUD919CL2Y
SpecPlus_000820
Spectrum5_001453
Spectrum_001838
U-98528E
pramipexole
5
Naltrexoneapproved, investigational, vet_approvedPhase 437816590-41-35360515
Synonyms:
16590-41-3
16676-29-2
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one
BIDD:GT0405
BPBio1_000146
BRD-K88172511-310-03-8
BRN 3596648
BSPBio_000132
C07253
CCRIS 3506
CHEBI:121459
CHEBI:7465
CHEMBL142
CID5360515
Celupan
D05113
DB00704
Depade
EINECS 240-649-9
EN-1639A
HMS2089O11
HS-0002
HSDB 6750
LS-92094
MLS002153483
MolPort-004-920-221
 
MorViva
N-Cyclopropylmethyl-14-hydroxydihydromorphinone
N-Cyclopropylmethylnoroxymorphone
Naltrexon
Naltrexona
Naltrexona [INN-Spanish]
Naltrexone
Naltrexone (USAN/INN)
Naltrexone Hcl
Naltrexone [USAN:BAN:INN]
Naltrexone [USAN:INN:BAN]
Naltrexone [Usan:Ban:Inn]
Naltrexonum
Naltrexonum [INN-Latin]
PDSP2_000847
PTI-555
Prestwick0_000116
Prestwick1_000116
Prestwick2_000116
Prestwick3_000116
ReVia
SMP1_000206
SPBio_002071
UM-792
UNII-5S6W795CQM
Vivitrex
Vivitrol
Vivitrol (TN)
naltrexone
naltrexone (ReVia)
6
CarbidopaapprovedPhase 4, Phase 3, Phase 2, Phase 117728860-95-934359, 38101
Synonyms:
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(S)-(-)-carbidopa
(S)-(-)-carbidopa hydrate
(S)-(−)-carbidopa
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-carbidopa hydrate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C-DOPA
C126_SIGMA
C1335_SIGMA
CCRIS 5093
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
Carbidopa (anhydrous)
Carbidopa Anhydrous
Carbidopa Monohydrate
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa, (S)-Isomer
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
 
Carbidopum
Carbidopum [INN-Latin]
DB00190
EINECS 249-271-9
EU-0100382
HMS2089B12
Hadrazino-alpha-methyldopa
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
L-α-methyldopahydrazine
LS-77199
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
Methyldopahydrazine
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S(-)-CARBIDOPA
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
carbidopa
carbidopum monohydricum
7
Selegilineapproved, investigational, vet_approvedPhase 4, Phase 22714611-51-926757, 5195
Synonyms:
(-)-(N)-Methyl-N-((1R)-1-methyl-2-phenylethyl)prop-2-yn-1-amine
(-)-Deprenil
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
(R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine
(R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin
(−)-selegiline
14611-51-9
14611-52-0 (hydrochloride)
2079-54-1 (deprenyl.hydrochloride)
AC1L1BTZ
AC1Q2860
AKOS000281115
Anipryl
Apo-Selegiline
BPBio1_000687
BRD-K86434416-001-02-7
BRD-K86434416-003-03-1
BSPBio_000623
BSPBio_001589
C07245
C13H17N
CHEBI:9086
CHEMBL972
CID26757
Carbex
D03731
DB01037
Deprenyl
Eldepryl
Emsam
Emsam (TN)
Gen-Selegiline
HMS1791P11
HMS1989P11
HMS2089D09
Humex
 
Jumex
L-Deprenalin
L-Deprenyl
LS-30156
MolPort-000-883-771
N-methyl-N-[(1R)-1-methyl-2-phenylethyl]prop-2-yn-1-amine
N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine
NCGC00024994-01
NCGC00024994-02
NCGC00024994-03
NCGC00024994-04
Novo-Selegiline
Nu-Selegiline
Prestwick0_000552
Prestwick1_000552
Prestwick2_000552
Prestwick3_000552
SPBio_002544
STK640578
Sd Deprenyl
Selegeline Hcl
Selegilina
Selegilina [INN-Spanish]
Selegiline (USAN/INN)
Selegiline Transdermal System (STS) patch
Selegiline [INN:BAN]
Selegiline, (R)-Isomer
Selegilinum
Selegilinum [INN-Latin]
Selegyline
Tocris-1095
UNII-2K1V7GP655
Yumex
ZINC19632633
Zelapar
l-E 250
selegiline
8
Ropiniroleapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 17391374-20-8, 91374-21-95095, 497540
Synonyms:
1,3-Dihydro-4-(2-(dipropylamino)ethyl)-2H-indol-2-one monohydrochloride
2(H)-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, monohydrochloride
2H-Indol-2-one, 1,3-dihydro-4-(2-(dipropylamino)ethyl)-, monohydrochloride
2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, hydrochloride (1:1)
4-(2-(Dipropylamino)ethyl)-2-indolinone monohydrochloride
4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one
4-[2-(Dipropylamino)ethyl]indoline-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one hydrochloride
91374-20-8
91374-20-8 (hydrochloride)
91374-21-9
91374-21-9 (Parent)
AB1004799
AC-735
AC1L1JLL
AC1L2ABS
AC1Q3EQJ
AR-1L3132
Adartrel
BIDD:GT0826
BRD-K15933101-003-01-2
C07564
CHEBI:8888
CHEMBL1200411
CHEMBL589
CID5095
CID68727
D00784
D08489
DB00268
EU-0101101
HMS2093K04
I06-0692
I06-0693
JZP-7
L000520
LS-83828
LS-83890
Lopac-R-4152
Lopac0_001101
 
MolPort-003-666-598
MolPort-003-987-439
NCGC00015893-01
NCGC00015893-04
NCGC00094373-01
NCGC00096064-01
NCGC00096064-02
NVD-434
R 4152
ReQuip
ReQuip CR
ReQuip LP
ReQuip XL
ReQuip XR
Repreve
Requip (TN)
Ropinirol
Ropinirol [INN-Spanish]
Ropinirole
Ropinirole (INN)
Ropinirole HCl
Ropinirole [INN:BAN]
Ropinirole hydrochloride
Ropinirole hydrochloride (JAN/USAN)
Ropinirole hydrochloride [USAN]
Ropinirolum
Ropinirolum [INN-Latin]
Ropitor
Ropitor (TN)
SK&F 101468
SK&F 101468-A
SK&F-101,468
SK&F-101468-A
SK&F-101468A
SKF 101468
SKF 101468-A
SPECTRUM1505178
ST51051236
TL8005858
TL8005859
UNII-030PYR8953
UNII-D7ZD41RZI9
ropinirol
9
AmantadineapprovedPhase 4, Phase 3, Phase 267768-94-52130
Synonyms:
1-Adamantamine
1-Adamantanamine
1-Adamantanamine (8CI)
1-Adamantylamine
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
1-adamantanamine
1-adamantylamine
1-aminoadamantane
138576_ALDRICH
665-66-7 (hydrochloride)
768-94-5
AB00514655
AC-11992
AC1L1CZI
AC1Q4UAF
AC1Q5396
ADAMANTANE,1-AMINO
AKOS000113994
AKOS000119324
Adamantamine
Adamantanamine
Adamantylamine
Amant
Amantadina
Amantadina [INN-Spanish]
Amantadine
Amantadine (INN)
Amantadine Base
Amantadine HCL
Amantadine Hydrochloride
Amantadine [INN:BAN]
Amantadinum
Amantadinum [INN-Latin]
Amantidine
Ambap768-94-5
Aminoadamantane
BIA4304
BIDD:GT0757
BPBio1_000368
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
Bio-0821
C06818
C10H17N
CHEBI:2618
CHEMBL660
CID2130
D07441
DB00915
DivK1c_000815
EINECS 212-201-2
Endantadine
Gen-Amantadine
HMS1791O12
HMS1989O12
HSDB 3202
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
KBio1_000815
KBio2_000390
 
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
L000868
LS-157049
Lopac-A-1260
Lopac0_000004
Mantadine
MolPort-001-661-700
MolPort-001-760-587
MolPort-001-791-102
NCGC00015036-01
NCGC00015036-07
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
NINDS_000815
NSC 341865
NSC341865
NSC83653
OR14310
Oprea1_248648
Pk-Merz
Pk-merz
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
SPBio_000002
SPBio_002273
STK298781
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
Spectrum_000030
Symadine
Symmetrel
TCMDC-125869
TL8005280
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-ylamine
Tricyclo[3.3.1.1(3,7)]decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
UNII-BF4C9Z1J53
Viregyt
Virosol
WLN: L66 B6 A B- C 1B ITJ BZ
Wiregyt
adamantan-1-amine
adamantan-1-ylamine
amantadine
amantadine hydrochloride
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
10
Methylphenidateapproved, investigationalPhase 4373113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
 
Methyl phenidyl acetate
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
11
AcetylcholineapprovedPhase 4, Phase 277651-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
12
Rivastigmineapproved, investigationalPhase 4, Phase 383123441-03-277991
Synonyms:
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
123441-03-2
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate
AB1004572
AC1L2U92
BIDD:GT0316
C11766
CHEMBL636
CID77991
Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester
Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
D03822
DB00989
ENA 713 free base
 
Ena 713 Free Base
Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Exelon
Exelon Patch
HMS2089H18
I06-2037
LS-172571
MolPort-003-666-662
NCGC00167531-01
Rivastigmine (JAN/USAN/INN)
Rivastigmine Hydrogen Tartrate
Rivastigmine [USAN:INN]
Rivastigmine hydrogen tartrate
SDZ 212-713
UNII-PKI06M3IW0
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
rivastigmine
13
CabergolineapprovedPhase 44681409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
14
Entacaponeapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 151130929-57-65281081
Synonyms:
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
(E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
(e)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
116314-67-1
130929-57-6
2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
AC-393
AC1NQY02
BIDD:GT0026
C071192
C07943
C14H15N3O5
CHEBI:4798
CHEMBL953
CID5281081
COM-998
Comtan
Comtan (TN)
Comtess
D00781
 
DB00494
ENTACAPONE
Entacapona
Entacapona [INN-Spanish]
Entacapone
Entacapone (JAN/USAN/INN)
Entacapone [USAN:INN]
Entacapone [Usan:Inn]
Entacaponum
Entacaponum [INN-Latin]
HMS2089O16
KB475572
LS-123327
LS-172316
MolPort-003-847-054
N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
NCGC00164555-01
Novartis brand of entacapone
OR 611
OR-611
Orion brand of entacapone
UNII-4975G9NM6T
entacapone
15
DonepezilapprovedPhase 4, Phase 3, Phase 2280120014-06-43152
Synonyms:
( inverted exclamation markA)-E 2020
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
120014-06-4
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC-6969
AC1L1FAE
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
 
Donepezil
Donepezil (INN)
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum5_001662
Spectrum_001664
TL8000531
UNII-8SSC91326P
16
Tadalafilapproved, investigationalPhase 4149171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
17
FesoterodineapprovedPhase 460286930-02-7, 286930-03-86918558
Synonyms:
FESO
 
Fesoterodine
Toviaz
18
Ergocalciferolapproved, nutraceuticalPhase 4123250-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
19
Cholecalciferolapproved, nutraceuticalPhase 485167-97-06221, 10883523, 5280795
Synonyms:
()-Vitamin D3
(+)-Vitamin D3
(+)-vitamin D3
(1S,3Z)-3-[(2e)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7e)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-Secocholesta-5,7,10-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7e)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
3-beta,Z,7E-9,10-Secocholestr-5,7,10(19)-trien-3-ol
47763_SUPELCO
57651-82-8
67-97-0
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
9,10-Secocholesta-5,7,10(19)-trien-3-ol
9,10-Secocholesta-5,7,10-trien-3-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
Activated 7-dehydrocholesterol
Arachitol
BPBio1_000460
BSPBio_000418
BSPBio_002408
Bio-0845
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
CID7067440
CID7251172
CID7251174
CID9821465
Calciol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol D3
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferolum
 
Colecalciferol
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Devaron
DivK1c_006276
Duphafral D3 1000
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
Ebivit
FeraCol
Granuvit D3
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC-375571
NSC375571
Oleovitamin D3
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Prestwick_63
Provitamine
Provitina
Quintox
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SR-05000001559
SR-05000001559-3
ST057172
SpecPlus_000180
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
Spectrum_001163
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
VITAMIN D
VITAMIN D3 POWDER
VITAMIN_D3
Vi-De3
Vi-de-3-hydrosol
VidDe-3-hydrosol
Videkhol
Vigantol
Vigorsan
Vitamin D3
Vitamin D3 emulsifiable
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
bmse000507
calciol
cholecalciferol
delta-D
vitamin d-3
20Dopamine agonistsPhase 4, Phase 3, Phase 2, Phase 1618
21AnestheticsPhase 4, Phase 39001
22N 0437Phase 4, Phase 3, Phase 2, Phase 186
23Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 117734
24DihydroxyphenylalaninePhase 4, Phase 3, Phase 2140
25Dopamine AgentsPhase 4, Phase 3, Phase 2, Phase 13759
26Dopamine Uptake InhibitorsPhase 4, Phase 31305
27Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
28Neuroprotective AgentsPhase 4, Phase 3, Phase 2, Phase 11672
29Neurotransmitter Uptake InhibitorsPhase 4, Phase 33464
30Protective AgentsPhase 4, Phase 3, Phase 2, Phase 17190
31AntioxidantsPhase 4, Phase 3, Phase 22928
32Cholinesterase InhibitorsPhase 4, Phase 3, Phase 2570
33Central Nervous System StimulantsPhase 4, Phase 22132
34Antiparkinson AgentsPhase 4, Phase 3, Phase 2, Phase 11527
35Cholinergic AgentsPhase 4, Phase 3, Phase 23846
36abobotulinumtoxinAPhase 4, Phase 2626
37Cholinergic AntagonistsPhase 4, Phase 21658
38Muscarinic AntagonistsPhase 4, Phase 21134
39onabotulinumtoxinAPhase 4, Phase 2626
40incobotulinumtoxinAPhase 4, Phase 2635
41Botulinum ToxinsPhase 4, Phase 2669
42Botulinum Toxins, Type APhase 4, Phase 2630
43Vasodilator AgentsPhase 4, Phase 13438
44Phosphodiesterase 5 InhibitorsPhase 4571
45Antiviral AgentsPhase 4, Phase 3, Phase 29732
46BenserazidePhase 4, Phase 3, Phase 218
47Benserazide, levodopa drug combinationPhase 4, Phase 2, Phase 316
48Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 121402
49Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 26260
50Carbidopa, levodopa drug combinationPhase 4, Phase 3, Phase 2, Phase 1120

Interventional clinical trials:

(show top 50)    (show all 264)
idNameStatusNCT IDPhase
1Emotion, Mood and Executive Function in Parkinson`s Disease (PD)Unknown statusNCT01385735Phase 4
2Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And ApathyCompletedNCT01782222Phase 4
3Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated PainCompletedNCT01744496Phase 4
4A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's DiseaseCompletedNCT01485172Phase 4
5A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's DiseaseCompletedNCT01494532Phase 4
6Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United StatesCompletedNCT00143026Phase 4
7Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's DiseaseCompletedNCT00640159Phase 4
8Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)CompletedNCT00632762Phase 4
9Levodopa Benserazide Generic Formulation Versus the OriginatorCompletedNCT02741947Phase 4
10Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's DiseaseCompletedNCT01662414Phase 4
11Validation of Dyskinesia Rating ScalesCompletedNCT01071395Phase 4
12Study to Evaluate Initiation of Stalevo in Early Wearing-offCompletedNCT00462007Phase 4
13Naltrexone for Impulse Control Disorders in Parkinson's DiseaseCompletedNCT01052831Phase 4
14Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor SymptomsCompletedNCT01300819Phase 4
15Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's DiseaseCompletedNCT00304161Phase 4
16Motor Response to Sildenafil in PDCompletedNCT01941732Phase 4
17A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's DiseaseCompletedNCT01711866Phase 4
18The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking ProblemsCompletedNCT00988117Phase 4
19A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing SurgeryCompletedNCT00594464Phase 4
20Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease PatientsCompletedNCT01523301Phase 4
21Effects of Rasagiline on Sleep Disturbances in Parkinson's DiseaseCompletedNCT01442610Phase 4
22Methylphenidate for the Treatment of Gait Impairment in Parkinson's DiseaseCompletedNCT00526630Phase 4
23Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's DiseaseCompletedNCT00219284Phase 4
24Cardiac Valve Complications in Prolactinomas Treated With CabergolineCompletedNCT00460616Phase 4
25Mild Cognitive Impairment in Parkinson's DiseaseCompletedNCT01519271Phase 4
26Amantadine for Improving Neurologic Symptoms in Ataxia-TelangiectasiaCompletedNCT00950196Phase 4
27Sagene 2014 - Parkinson's Disease and Erectile DysfunctionRecruitingNCT02225548Phase 4
28Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational TreatmentRecruitingNCT02365870Phase 4
29Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal SymptomsRecruitingNCT02775591Phase 4
30Energy Metabolism and Cognitive AgingRecruitingNCT00777010Phase 4
31Care for Late Stage ParkinsonismRecruitingNCT02333175Phase 4
32The Use of Botox in Advanced Parkinson's Patients Experiencing PainActive, not recruitingNCT02472210Phase 4
33Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson DiseaseNot yet recruitingNCT03011476Phase 4
34Fesoterodine on Urgency Episodes in Parkinson's Disease PopulationNot yet recruitingNCT02385500Phase 4
35Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing OffTerminatedNCT00642356Phase 4
36Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's DiseaseTerminatedNCT01519882Phase 4
37Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's DiseaseTerminatedNCT00462254Phase 4
38Clinical Effects of Vitamin D Repletion in Patients With Parkinson's DiseaseTerminatedNCT00571285Phase 4
39Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's DiseaseTerminatedNCT01178047Phase 4
40Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's DiseaseTerminatedNCT01048229Phase 4
41Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity TremorUnknown statusNCT00724906Phase 3
42A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.CompletedNCT01929317Phase 3
43A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's DiseaseCompletedNCT01176240Phase 3
44A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-DopaCompletedNCT01154166Phase 3
45Safety and Tolerability Trial of Switching From Ropinirole to RotigotineCompletedNCT00593606Phase 3
46Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine AgonistCompletedNCT00643045Phase 3
47A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's DiseaseCompletedNCT01723904Phase 3
48The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsCompletedNCT00286897Phase 3
49Efficiency of Physiotherapeutic Care in Parkinson's DiseaseCompletedNCT00330694Phase 3
50Carbidopa-Levodopa Extended-Release (CD-LD ER) Alone or in Combination With Carbidopa-Levodopa Immediate Release (IR) to IPX066 Followed by Extension Safety Study of IPX066 in Subjects With Advanced Parkinson's DiseaseCompletedNCT01411137Phase 3

Search NIH Clinical Center for Parkinson Disease 8

Genetic Tests for Parkinson Disease 8

About this section

Genetic tests related to Parkinson Disease 8:

id Genetic test Affiliating Genes
1 Parkinson Disease 8, Autosomal Dominant26

Anatomical Context for Parkinson Disease 8

About this section

MalaCards organs/tissues related to Parkinson Disease 8:

35
Brain, Eye, Testes, Liver, Bone

Animal Models for Parkinson Disease 8 or affiliated genes

About this section

MGI Mouse Phenotypes related to Parkinson Disease 8:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053948.9CTNNB1, PINK1, SNCA
2MP:00053858.8CTNNB1, LRRK2, PARK2, PINK1, SNCA
3MP:00030128.7CTNNB1, LRRK2, PARK2, PINK1, SNCA
4MP:00053908.5CTNNB1, LRRK2, PARK2, PINK1, SNCA
5MP:00053868.0CTNNB1, LRRK2, PARK2, PARK7, PINK1, SNCA
6MP:00053848.0CTNNB1, LRRK2, PARK2, PARK7, PINK1, SNCA
7MP:00053767.9CTNNB1, LRRK2, PARK2, PARK7, PINK1, SNCA
8MP:00036317.9CTNNB1, LRRK2, PARK2, PARK7, PINK1, SNCA

Publications for Parkinson Disease 8

About this section

Variations for Parkinson Disease 8

About this section

UniProtKB/Swiss-Prot genetic disease variations for Parkinson Disease 8:

69 (show all 21)
id Symbol AA change Variation ID SNP ID
1LRRK2p.Arg1067GlnVAR_024938rs111341148
2LRRK2p.Ile1122ValVAR_024940rs34805604
3LRRK2p.Ser1228ThrVAR_024941rs60185966
4LRRK2p.Arg1441GlyVAR_024946rs33939927
5LRRK2p.Arg1441HisVAR_024947rs34995376
6LRRK2p.Arg1514GlnVAR_024948rs35507033
7LRRK2p.Pro1542SerVAR_024949rs33958906
8LRRK2p.Val1598GluVAR_024950rs721710
9LRRK2p.Tyr1699CysVAR_024954rs35801418
10LRRK2p.Met1869ThrVAR_024955rs35602796
11LRRK2p.Arg1941HisVAR_024956rs77428810
12LRRK2p.Ile2012ThrVAR_024957rs34015634
13LRRK2p.Gly2019SerVAR_024958rs34637584
14LRRK2p.Ile2020ThrVAR_024959rs35870237
15LRRK2p.Thr2356IleVAR_024963rs113511708
16LRRK2p.Met712ValVAR_054741rs199566791
17LRRK2p.Arg1728HisVAR_054744rs145364431
18LRRK2p.Arg1728LeuVAR_054745rs145364431
19LRRK2p.Thr2141MetVAR_054747rs111691891
20LRRK2p.Arg2143HisVAR_054748rs201271001
21LRRK2p.Leu2466HisVAR_054750rs281865057

Clinvar genetic disease variations for Parkinson Disease 8:

5 (show all 15)
id Gene Variation Type Significance SNP ID Assembly Location
1LRRK2NM_198578.3(LRRK2): c.4321C> G (p.Arg1441Gly)SNVPathogenicrs33939927GRCh37Chr 12, 40704236: 40704236
2LRRK2NM_198578.3(LRRK2): c.5096A> G (p.Tyr1699Cys)SNVPathogenicrs35801418GRCh37Chr 12, 40714916: 40714916
3LRRK2NM_198578.3(LRRK2): c.4321C> T (p.Arg1441Cys)SNVPathogenicrs33939927GRCh37Chr 12, 40704236: 40704236
4LRRK2NM_198578.3(LRRK2): c.3364A> G (p.Ile1122Val)SNVPathogenicrs34805604GRCh37Chr 12, 40692927: 40692927
5LRRK2NM_198578.3(LRRK2): c.6055G> A (p.Gly2019Ser)SNVPathogenicrs34637584GRCh37Chr 12, 40734202: 40734202
6LRRK2NM_198578.3(LRRK2): c.6059T> C (p.Ile2020Thr)SNVPathogenicrs35870237GRCh37Chr 12, 40734206: 40734206
7LRRK2NM_198578.3(LRRK2): c.4322G> A (p.Arg1441His)SNVPathogenicrs34995376GRCh37Chr 12, 40704237: 40704237
8LRRK2NM_198578.3(LRRK2): c.7153G> A (p.Gly2385Arg)SNVPathogenic, risk factorrs34778348GRCh37Chr 12, 40757328: 40757328
9LRRK2NM_198578.3(LRRK2): c.1256C> T (p.Ala419Val)SNVPathogenicrs34594498GRCh37Chr 12, 40646786: 40646786
10LRRK2NM_198578.3(LRRK2): c.2264C> T (p.Pro755Leu)SNVPathogenicrs34410987GRCh37Chr 12, 40677699: 40677699
11LRRK2NM_198578.3(LRRK2): c.3342A> G (p.Leu1114=)SNVPathogenicrs35808389GRCh37Chr 12, 40692290: 40692290
12LRRK2NM_198578.3(LRRK2): c.4309A> C (p.Asn1437His)SNVPathogenicrs74163686GRCh37Chr 12, 40703027: 40703027
13LRRK2NM_198578.3(LRRK2): c.4883G> C (p.Arg1628Pro)SNVPathogenicrs33949390GRCh37Chr 12, 40713845: 40713845
14LRRK2NM_198578.3(LRRK2): c.5605A> G (p.Met1869Val)SNVPathogenicrs281865052GRCh37Chr 12, 40717057: 40717057
15LRRK2NM_198578.3(LRRK2): c.5620G> T (p.Glu1874Ter)SNVPathogenicrs281865054GRCh37Chr 12, 40717072: 40717072

Expression for genes affiliated with Parkinson Disease 8

About this section
Search GEO for disease gene expression data for Parkinson Disease 8.

GO Terms for genes affiliated with Parkinson Disease 8

About this section

Cellular components related to Parkinson Disease 8 according to GeneCards Suite gene sharing:

(show all 17)
idNameGO IDScoreTop Affiliating Genes
1inclusion bodyGO:001623410.3LRRK2, SNCA
2Wnt signalosomeGO:199090910.3CTNNB1, LRRK2
3Lewy bodyGO:009741310.1PARK2, PINK1
4postsynapseGO:009879410.0LRRK2, SNCA
5mitochondrial respiratory chain complex IGO:00057479.9PARK7, SNCA
6terminal boutonGO:00431959.8LRRK2, SNCA
7presynapseGO:00987939.7PARK2, PARK7
8mitochondrial intermembrane spaceGO:00057589.6PARK7, PINK1
9synapseGO:00452029.3CTNNB1, LRRK2, SNCA
10cell bodyGO:00442979.2PARK7, PINK1
11neuron projectionGO:00430059.0LRRK2, PARK2, PARK7
12cell junctionGO:00300549.0CTNNB1, LRRK2, SNCA
13axonGO:00304248.1LRRK2, PARK7, PINK1, SNCA
14perinuclear region of cytoplasmGO:00484717.9CTNNB1, PARK2, PARK7, PINK1, SNCA
15mitochondrionGO:00057397.9LRRK2, PARK2, PARK7, PINK1, SNCA
16cytosolGO:00058297.3CTNNB1, LRRK2, PARK2, PARK7, PINK1, SNCA
17cytoplasmGO:00057376.8CTNNB1, LRRK2, PARK2, PARK7, PINK1, SNCA

Biological processes related to Parkinson Disease 8 according to GeneCards Suite gene sharing:

(show all 50)
idNameGO IDScoreTop Affiliating Genes
1cellular response to manganese ionGO:007128710.2LRRK2, PARK2
2regulation of canonical Wnt signaling pathwayGO:006082810.0LRRK2, PARK2
3cellular response to toxic substanceGO:009723710.0PARK2, PINK1
4negative regulation of autophagosome assemblyGO:190290210.0LRRK2, PINK1
5negative regulation of macroautophagyGO:001624210.0LRRK2, PINK1
6regulation of neuron deathGO:190121410.0LRRK2, SNCA
7regulation of neurotransmitter secretionGO:004692810.0PARK2, SNCA
8excitatory postsynaptic potentialGO:00600799.9LRRK2, SNCA
9regulation of protein targeting to mitochondrionGO:19032149.9PARK2, PINK1
10cellular response to dopamineGO:19033519.9LRRK2, PARK2
11negative regulation of hydrogen peroxide-induced cell deathGO:19032069.9LRRK2, PARK7
12mitophagyGO:00004229.9PARK2, PINK1
13protein destabilizationGO:00316489.9PARK2, SNCA
14cellular response to fibroblast growth factor stimulusGO:00443449.8CTNNB1, SNCA
15negative regulation of reactive oxygen species metabolic processGO:20003789.8PARK2, PINK1
16negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayGO:19033779.8PARK2, PARK7
17protein localization to mitochondrionGO:00705859.8LRRK2, PARK2
18negative regulation of JNK cascadeGO:00463299.8PARK2, PINK1
19regulation of mitochondrion organizationGO:00108219.7PARK2, PINK1
20synaptic vesicle transportGO:00484899.7CTNNB1, SNCA
21positive regulation of mitochondrial fissionGO:00901419.7PARK2, PINK1
22positive regulation of mitochondrial electron transport, NADH to ubiquinoneGO:19029589.7PARK7, PINK1
23negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathwayGO:19033849.7PARK7, PINK1
24regulation of protein ubiquitinationGO:00313969.7PARK2, PINK1
25negative regulation of protein sumoylationGO:00332349.7CTNNB1, PARK7
26regulation of neuron apoptotic processGO:00435239.6PARK7, PINK1
27activation of protein kinase B activityGO:00321489.6PARK7, PINK1
28regulation of synaptic vesicle transportGO:19028039.6LRRK2, PARK2, PINK1
29regulation of locomotionGO:00400129.5LRRK2, SNCA
30negative regulation of oxidative stress-induced neuron deathGO:19032049.5PARK7, PINK1
31regulation of dopamine secretionGO:00140599.4PARK2, SNCA
32response to oxidative stressGO:00069799.3LRRK2, PARK2, PINK1
33positive regulation of I-kappaB kinase/NF-kappaB signalingGO:00431239.3CTNNB1, PARK2, PINK1
34dopamine uptake involved in synaptic transmissionGO:00515839.3PARK2, PARK7, SNCA
35negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayGO:19022369.2LRRK2, PARK2, PARK7
36regulation of reactive oxygen species metabolic processGO:20003779.2PARK2, PINK1, SNCA
37negative regulation of oxidative stress-induced cell deathGO:19032029.2PARK2, PARK7, PINK1
38dopamine metabolic processGO:00424179.1PARK2, SNCA
39regulation of mitochondrial membrane potentialGO:00518819.1PARK2, PARK7, PINK1
40positive regulation of sequence-specific DNA binding transcription factor activityGO:00510919.0CTNNB1, PARK7, PINK1
41adult locomotory behaviorGO:00083448.9PARK2, PARK7, SNCA
42protein stabilizationGO:00508218.8PARK2, PARK7, PINK1
43positive regulation of peptidyl-serine phosphorylationGO:00331388.8PARK7, PINK1, SNCA
44negative regulation of protein phosphorylationGO:00019338.6LRRK2, PARK2, PARK7, SNCA
45synaptic transmission, dopaminergicGO:00019638.5PARK2, PARK7, SNCA
46cellular response to oxidative stressGO:00345998.5LRRK2, PARK7, PINK1, SNCA
47mitochondrion organizationGO:00070058.5LRRK2, PARK2, PARK7, PINK1
48negative regulation of gene expressionGO:00106298.4CTNNB1, PARK2, PARK7, PINK1
49negative regulation of neuron apoptotic processGO:00435248.2PARK2, PARK7, PINK1, SNCA
50negative regulation of neuron deathGO:19012158.2CTNNB1, LRRK2, PARK2, PARK7, SNCA

Molecular functions related to Parkinson Disease 8 according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1tubulin bindingGO:001563110.0LRRK2, PARK2
2phospholipase bindingGO:00432749.8PARK2, SNCA
3repressing transcription factor bindingGO:00704919.6CTNNB1, PARK7
4androgen receptor bindingGO:00506819.6CTNNB1, PARK7
5copper ion bindingGO:00055079.5PARK7, SNCA
6ubiquitin-specific protease bindingGO:19903819.5PARK2, PARK7
7kinase bindingGO:00199009.0CTNNB1, PARK2, PARK7
8identical protein bindingGO:00428028.2LRRK2, PARK2, PARK7, SNCA
9enzyme bindingGO:00198998.2CTNNB1, PARK2, PARK7, SNCA

Sources for Parkinson Disease 8

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet